863OAxitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results. (23rd October 2018) - Gross-Goupil, M; Kwon, T G; Eto, M; Ye, D; Miyake, H; Seo, S I; Byun, S S; Lee, J L; Master, V; Jin, J; Debenedetto, R; Linke, R; et al.